Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily Keywords: complement; complement inhibition; COVID-19; thrombotic microangiopathy EN complement complement inhibition COVID-19 thrombotic microangiopathy e227 e230 4 06/18/20 20200615 NES 200615 Recent evidence suggests that signs and symptoms of severe COVID-19 infection resemble more the pathophysiology and phenotype of complement-mediated thrombotic microangiopathies (TMA), rather than sepsis-induced coagulopathy or disseminated intravascular coagulation (DIC).[[1]] Since effective treatment is available for complement-mediated TMA,[3] we aim to systematically describe relevant features (clinical phenotype, pathophysiology and management) in patients with severe COVID-19 infection. Since C3 and the lectin pathway have been implicated in the pathophysiology of coronavirus infections, inhibitors of proximal complement pathways, under clinical development for complement-mediated TMAs, could also be efficacious in COVID-19 infections.[Extracted from the article]

Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. Copyright applies to all Abstracts.